Breast Cancer
A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)
- Details
ClinicalTrials.gov ID:
NCT05501886
Diagnosis Type:
NA
USOR Number:
- Address
265 North Broadway
Portland, OR 97227
P: (503) 280-1223
